Oxford Biomedica. 2005 to see 'Huge value creation' (EVO) (OXB)

Glad the Daily Spail has come out with the positive broker BUY recommendation.

The combination of a weekend press report of the buy recommendation is doubly valuable, short term ( ie months?) 40p.
- davidbennet,
agree that the potential even up at 40 p region again would be to hold for Trovax deal, or buyout, plus the immense potential of the following on treatments for Parkinsons and Nerve damage. THESE interest me more than Trovax - as they do Dr Alan Kingsman, if truth be told.
OXB with increased funding, now represents the best Biotech investment in the UK and by implication the US markets too - next to Novartis ( which pipped OXB as the 'best pipeline of treatments in UK Bios' ) recently.

American and other investors - and traders, I must also speak as one of these - really will see OXB as a very cheap way into a fine portfolio of well funded and extremely potent OXFORD based treatments.

I said twice here in the past year that OXB ARE the 'new British Biotech' and by that I meant they are fast becoming the FLAGSHIP of UK technology innovative treatment development and excellence of project development and graduate staff input .
H.